會議?1:?Protein & Antibody Engineering?蛋白質與抗體工程

在中國舉辦聚焦于蛋白質工學與抗體工學的會議

近年中國在全球生物醫(yī)藥產業(yè)中崛起，其真正價值不僅在監(jiān)管機構的指導體制及審核路徑上、在新生物學治療藥物研發(fā)成果上也面臨考驗。2017年3月28日至30日在中國上海舉辦的第4屆PEGS Summit，制藥企業(yè)高層與意見領袖齊聚一堂，針對創(chuàng)新的創(chuàng)藥議程、尖端技術成果、解決問題的最佳實例與學習等主題展開熱烈的討論。

2017年焦點：免疫療法作為癌癥治療創(chuàng)新方法的重要性日益升高，學會也新增了「癌癥免疫」相關分組討論會。本次會議不僅限于中國，將介紹全球制藥公司開發(fā)免疫療法相關產品的生產線與計畫發(fā)展狀況。

Preliminary Agenda

蛋白質與抗體工程

本單元以蛋白質及抗體工程為主題，研究機關與藥廠研究人員將分享蛋白質及抗體分子的設計、新藥發(fā)現、工程研究成果，并討論克服開發(fā)過程中所遇到各類課題的創(chuàng)新策略。

暫定議程

聯(lián)合主題演講

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

DISPLAY LIBRARIES

A Novel Platform for Human Antibody Discovery Using Yeast Display Antibody Library

Aichi Zhao, Ph.D., President, R&D, OriMabs, Ltd.

Recombinant Antibody Display Libraries - Design, Construction and Selection

Eunice Zhou, Ph.D., Associate Adjunct Professor, Anesthesia, UC San Francisco

蛋白質及抗體產生

Generation of Humanized Antibody Transgenic Animal (Camouse) for Producing Human Antibody

Liangpeng Ge, Ph.D., Director, Institute of Bingengineering, Chongqing Academy of Animal Sciences

New Techniques for in vitro Evolution and Selection of Enzymes

Manfred Konrad, Ph.D., Max-Planck Institute for Biophysical Chemistry, Head, Enzyme Biochemistry Laboratory

蛋白質與標靶工程

Case Study
Engineering G-Protein Coupled Receptors for High Production and Efficient Folding In Synthetic Environments

Frank Bernhard, Ph.D., Lab Manager, Biophysical Chemistry, Goethe University Frankfurt

Computationally-Driven Engineering of an Anti-Tumor Antibody

Chris Bailey-Kellogg, Ph.D., Professor, Computer Science, University of Dartmouth

新生物學治療藥物開發(fā)

Engineering Anti-VEGFR2 X Anti-PDGFR-Beta Bispecific Antibodies for the Treatment of Cancer and Ophthalmological Diseases

Zhenping Zhu, Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corp, LLC.

Nexmab Antibody-Drug Conjugate for the Treatment of Ovarian Cancer

Sunbae Lee, Ph.D., Senior Research Scientist, R&D Center, Alteogen, Inc.

* 活動內容有可能不事先告知作更動及調整。

蛋白質聚集與穩(wěn)定性

近年，蛋白質聚集、粒子、sub-visible particle相關研究變得越來越重要。聚集形成的機制，以及其發(fā)展和配方的影響，已成為許多研究與討論的主題。在本單元中，除了將分享動力學研究成果以深入理解聚集原因，也聚焦提升穩(wěn)定性和控制聚集的分析及配方策略。

暫定議程

聯(lián)合主題演講

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

聚集形成

Determinant Factor for Aggregation and Fragment Formation: Oxidation

Joy Zhou, Ph.D., Principal Scientist, Associate Director, DP MST, Shire

Protein Aggregation during Formulation and Drug Product Manufacturing and Mitigation Strategies

Mark Yang Ph.D., Director, Fill Finish Development, BioPharmaceutical Development, Genzyme

發(fā)展性與處方開發(fā)的聚集分析

Aggregation Analysis at High and Low Concentrations

Jennifer McManus, Ph.D., Lecturer, Department of Chemistry, National University of Ireland Maynooth

How to Optimize Stability of Drug Substance and Drug Product through Integration of Rapid and Sensitive Analytical Tools with Rational Approach to Developability Assessment and Early Formulation Development

Danny Chou, Ph.D., President, Compassion BioSolutions, LLC.

Heavy Chain of Mouse IgM Can Be Cleaved Between CH1 and CH2 Domains by a Protease Present in Serum

Tomasz Klaus, MSc, Research Assistant, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow

穩(wěn)定性與傳輸裝置課題

Impact of Product Heterogeneity on Product Biological Activity and Stability in the Context of Bio-therapeutics

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd. (A Vitane Group of Companies)

Modified Phosphate Buffered Saline (PBS) as a Viable Vehicle for Biotherapeutic Drugs

Tatyana Mezhebovsky, Ph.D., Principal Scientist, BioFormulations, Sanofi US

* 活動內容有可能不事先告知作更動及調整。

癌癥免疫

本單元以癌癥免疫為主題，本領域意見領袖及先驅研究人員，將討論中國目前研究現況，并聚焦推動新分子至臨床研究階段的創(chuàng)新方法與尖端技術。

暫定議程

聯(lián)合主題演講

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Associate Professor, Oncology and Surgery, Gastrointestinal Cancer Program, Tumor Immunology Program, Johns Hopkins University School of Medicine

聯(lián)合會議－T細胞工程分析策略

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

中國癌癥領域PIPELINE與研究成果最新情報

Beyond PD-1: Challenge and Opportunity in Immuno-Oncology

Hongtao Lu, Ph.D., Executive Vice President & CSO, Discovery, Zai Laboratory

Improving the Efficacy of Immuno-Checkpoint Inhibitor through Target Mediated Antibody Recycling and Combination Interventions

Xueming Qian, Ph.D., Chairman & CEO, MabSpace Biosciences

Screening PD1 inhibitors and Beyond

Bo Chen, Ph.D., CEO, Shanghai Junshi

Updates on Alphamab's Molecules in the Clinic Targeting PDl-1 and CTLA-4

Ting Xu, Ph.D., CEO & President, Alphamab

The Design and Development of Novel Biologics for Cancer Immunotherapies

Jinming Gu, Ph.D., Executive Director, Biologics Discovery, Shanghai Hengrui Pharmaceutical Co., Ltd.

Novel Bispecific Antibody Technology for Cancer Immunotherapeutics

Chengbin Wu, Ph.D., CEO, Epimab

Amgen's BiTE Bispecific T-Cell Engaging Antibody for Immunotherapy

MingQiang Zhang, Ph.D., Head, R&D, Amgen Asia

Agonist Antibody in Immune-Oncology, in Mono- and Combination Therapies (tentative)

Peter Luo, Ph.D., CEO & Co-Founder, Adagene

* 活動內容有可能不事先告知作更動及調整。

生物學治療藥物表徵分析

本單元以生物學治療藥表徵分析為主題，將重點擺在提供各種能加速技術創(chuàng)新的方法，將透過具獨創(chuàng)性的策略及最新技術研究發(fā)表，分享有助開發(fā)具優(yōu)異特徵新生物學治療藥物的想法、專業(yè)知識、解決方案。

暫定議程

聯(lián)合主題演講

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Assistant Professor, Oncology and Gastrointestinal Cancer, Johns Hopkins University

聯(lián)合會議－T細胞工程的分析策略

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

優(yōu)化與發(fā)展性

Integrated Technology Solutions to Support Biologics Hit to Lead and Beyond

Han Li, Ph.D., Principal Scientist, Leads Discovery & Optimization, Bristol-Myers Squibb Company

Mutational Approaches to Improve the Biophysical Properties of Single Domain Antibodies

Jamshid Tanha, Ph.D., Senior Research Officer, Human Health Therapeutics Portfolio, National Research Council Canada

新BIOSIMILAR產品結構面與功能面表徵分析

Effects of Glycosylation on Biological Activities of Therapeutic Antibodies

Shan Chung, Ph.D., Senior Scientist and Group Leader, Bioanalytical Sciences, Genentech

Oxidative Post-Translational Modification - Impact on Stability and Formulation of Protein Therapeutics

Christian Schoeneich, Ph.D., Professor and Chair, Pharmaceutical Chemistry, University of Kansas Lawrence

Higher Order Structure Analysis of Antibodies by Hydrogen/Deuterium Exchange Mass Spectrometry

Susumu Uchiyama, Ph.D., Associate Professor, Graduate School of Engineering, Osaka University

Physicochemical and Functional Characterization of Biosimilar Bevacizumab

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd., India

* 活動內容有可能不事先告知作更動及調整。